Contrasting Generation Bio (NASDAQ:GBIO) & Anthera Pharmaceuticals (OTCMKTS:ANTH)

Generation Bio (NASDAQ:GBIO) and Anthera Pharmaceuticals (OTCMKTS:ANTH) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, institutional ownership, profitability and analyst recommendations.

Volatility & Risk

Generation Bio has a beta of 2.69, indicating that its share price is 169% more volatile than the S&P 500. Comparatively, Anthera Pharmaceuticals has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500.

Earnings & Valuation

This table compares Generation Bio and Anthera Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generation Bio	$18.58 million	2.08	-$126.61 million	($2.19)	-0.26
Anthera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Anthera Pharmaceuticals has lower revenue, but higher earnings than Generation Bio.

Profitability

This table compares Generation Bio and Anthera Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Generation Bio	-782.86%	-104.85%	-49.54%
Anthera Pharmaceuticals	N/A	N/A	N/A

Insider and Institutional Ownership

95.2% of Generation Bio shares are held by institutional investors. 21.1% of Generation Bio shares are held by insiders. Comparatively, 2.1% of Anthera Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and target prices for Generation Bio and Anthera Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generation Bio	0	0	2	0	3.00
Anthera Pharmaceuticals	0	0	0	0	0.00

Generation Bio presently has a consensus price target of $6.50, indicating a potential upside of 1,020.69%. Given Generation Bio’s stronger consensus rating and higher possible upside, research analysts clearly believe Generation Bio is more favorable than Anthera Pharmaceuticals.

Summary

Generation Bio beats Anthera Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

About Generation Bio

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.